Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Pilot Study: Ketamine for Acute Pain After Rattlesnake Envenomation


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05379179

Organisation Name: University of Arizona

Overal Status: Enrolling by invitation

Start Date: June 20, 2022

Last Update: September 13, 2022

Lead Sponsor: Meghan Spyres

Brief Summary: This is a pilot study to evaluate pain responses from two different approved medications (ketamine and fentanyl) in the treatment of pain after rattlesnake envenomation (RSE). Both medications are currently used in standard practice to treat both acute and chronic pain and are options for pain management after RSE. Multiple studies exist showing ketamine to be both safe and effective for the treatment of acute pain, and to be as good as or better than opioids for this indication. The specific comparison of ketamine to fentanyl, however, has never been studied for the treatment of acute pain after rattlesnake envenomation in the United States. The investigators plan to measure pain scores after a single dose of ketamine or fentanyl in patients shortly after being envenomated, followed by continued treatment of pain guided by the treating doctor. There will be no restrictions on additional pain medications given and no other changes to the treatment of these patients during their hospitalization. This research is important because pain after RSE can be difficult to control and may require frequent, high doses of opioids for several days. An effective non-opioid medication would be helpful both to better-control pain and to reduce exposure to opioids in this patient population. This study will compare patient-reported pain scores after receiving a single dose of ketamine or fentanyl in patients with rattlesnake bites who have been admitted to the toxicology service at Banner - University Medical Center Phoenix (BUMCP).

Conditions:
  • Rattlesnake Envenomation


Total execution time in seconds: 0.266597032547